Abstract
The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension. This syndrome is associated with increased risk of cardiovascular disease and is a common early abnormality in the development of type 2 diabetes. The pathogenesis of the syndrome has multiple origins. Obesity and sedentary lifestyle coupled with genetic factors interact to produce the syndrome. Here, we consider two components of the metabolic syndrome, dyslipidaemia and hypercoagulability.
Keywords: Metabolic syndrome, obesity, insulin resistance, dyslipidaemia, coagulation, ree fatty acids, high density lipoprotein, triglycerides
Current Vascular Pharmacology
Title: Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome
Volume: 4 Issue: 3
Author(s): Anna I. Kakafika, Evagelos N. Liberopoulos, Asterios Karagiannis, Vasilios G. Athyros and Dimitri P. Mikhailidis
Affiliation:
Keywords: Metabolic syndrome, obesity, insulin resistance, dyslipidaemia, coagulation, ree fatty acids, high density lipoprotein, triglycerides
Abstract: The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension. This syndrome is associated with increased risk of cardiovascular disease and is a common early abnormality in the development of type 2 diabetes. The pathogenesis of the syndrome has multiple origins. Obesity and sedentary lifestyle coupled with genetic factors interact to produce the syndrome. Here, we consider two components of the metabolic syndrome, dyslipidaemia and hypercoagulability.
Export Options
About this article
Cite this article as:
Kakafika I. Anna, Liberopoulos N. Evagelos, Karagiannis Asterios, Athyros G. Vasilios and Mikhailidis P. Dimitri, Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome, Current Vascular Pharmacology 2006; 4 (3) . https://dx.doi.org/10.2174/157016106777698432
DOI https://dx.doi.org/10.2174/157016106777698432 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry Antioxidant Activity of Two Wild Edible Mushrooms (Morchella vulgaris and Morchella esculanta) from North Turkey
Combinatorial Chemistry & High Throughput Screening The Effects of Olprinone, a Phosphodiesterase 3 Inhibitor, on Systemic and Cerebral Circulation
Current Vascular Pharmacology VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Copeptin in Preeclampsia Development
Current Women`s Health Reviews Editorial [Hot Topic: Murine Atherosclerosis (Part II) (Guest Editor: Godfrey S. Getz)]
Current Drug Targets Febuxostat: A Novel Non-Purine Selective Inhibitor of Xanthine Oxidase for the Treatment of Hyperuricemia in Gout
Recent Patents on Inflammation & Allergy Drug Discovery The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review
Current Cardiology Reviews Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches
Current Pharmaceutical Design PPARγ in Angiogenesis and Vascular Development
Current Angiogenesis (Discontinued) Fluoxetine and all other SSRIs are 5-HT<sub>2B</sub> Agonists - Importance for their Therapeutic Effects
Current Neuropharmacology The L-Type Ca2+ Channel as a Therapeutic Target in Heart Disease
Current Medicinal Chemistry Targeting of Antioxidant and Anti-Thrombotic Drugs to Endothelial Cell Adhesion Molecules
Current Pharmaceutical Design Periostin as a Heterofunctional Regulator of Cardiac Development and Disease
Current Genomics Food Bioactives versus Drugs – Introduction
Current Pediatric Reviews Autophagy Inhibition Rescues Against Leptin-Induced Cardiac Contractile Dysfunction
Current Pharmaceutical Design New Aspects of Cyclosporin A Mode of Action: from Gene Silencing to Gene Up-Regulation
Mini-Reviews in Medicinal Chemistry An update on the Management and Treatment of Deep Vein Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Risk and Benefit of Statins in Stroke Secondary Prevention
Current Vascular Pharmacology